Bahceci Ilkay, Yildiz Ilknur E, Duran Omer F, Soztanaci Umut S, Kirdi Harbawi Zeynep, Senol Feray F, Demiral Gokhan
Medical Microbiology, Recep Tayyip Erdoğan University, Medical Faculty, Rize, TUR.
Infectious Diseases, Recep Tayyip Erdoğan University, Medical Faculty, Rize, TUR.
Cureus. 2022 Feb 18;14(2):e22363. doi: 10.7759/cureus.22363. eCollection 2022 Feb.
Objective The aim of this study was to determine the factors and rates of secondary bacterial infections developed in patients after the diagnosis of COVID-19 and antimicrobial susceptibility to guide the empirical treatment and contribute to epidemiological data. Materials and Methods In our study, 1,055 patients diagnosed with COVID-19, hospitalized at Recep Tayyip Erdoğan University Training and Research Hospital, Rize, between the dates March 24, 2020 and December 31, 2020, were recruited. The diagnoses of all patients were confirmed by positive SARS-CoV-2 polymerase chain reaction (PCR) tests. In addition, the blood and respiratory tract cultures of the patients recruited in the study were analyzed retrospectively. Results Ninety-two (8.7%) patients were found to have microbiologically proven respiratory or circulatory tract infections via microbial culture results. Respiratory tract infections were detected as monomicrobial in 44 patients and as polymicrobial in 17 patients, among a total of 61 patients. In addition, 59 (64.1%) patients were male patients, and 33 (35.9%) were female patients. Among the microorganisms grown in blood cultures, - with a percentage of 31% and with a percentage of 27.5% were prominent. In respiratory tract cultures, constitutes the majority with a percentage of 33.3%, followed by and with a percentage of 9.5% each. The most resistant bacteria were , resistant to all antibiotics other than colistin. Conclusion Secondary bacterial infection rates in patients with COVID-19 are lower than influenza pandemic. However, the frequency of empirical antibiotics use seems relatively high.
目的 本研究旨在确定COVID-19确诊患者继发细菌感染的因素和发生率以及抗菌药物敏感性,以指导经验性治疗并为流行病学数据提供参考。
材料与方法 在我们的研究中,招募了2020年3月24日至2020年12月31日期间在里泽的雷杰普·塔伊普·埃尔多安大学培训与研究医院住院的1055例确诊为COVID-19的患者。所有患者的诊断均通过SARS-CoV-2聚合酶链反应(PCR)检测呈阳性得以证实。此外,对本研究中招募患者的血液和呼吸道培养物进行回顾性分析。
结果 通过微生物培养结果发现,92例(8.7%)患者存在经微生物学证实的呼吸道或循环系统感染。在总共61例呼吸道感染患者中,44例检测为单一微生物感染,17例检测为多微生物感染。此外,59例(64.1%)为男性患者,33例(35.9%)为女性患者。在血培养中生长的微生物中,[具体微生物1]占比31%,[具体微生物2]占比27.5%较为突出。在呼吸道培养物中,[具体微生物3]占比33.3%居多数,其次是[具体微生物4]和[具体微生物5],各占比9.5%。最耐药的细菌是[具体细菌名称],对除黏菌素外的所有抗生素均耐药。
结论 COVID-19患者的继发细菌感染率低于流感大流行。然而,经验性使用抗生素的频率似乎相对较高。